Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul 130-701, Republic of Korea.
J Cell Biochem. 2011 Dec;112(12):3594-603. doi: 10.1002/jcb.23290.
Pelubiprofen is a non-steroidal anti-inflammatory drugs (NSAIDs) that is related both structurally and pharmacologically to ibuprofen. Anti-inflammatory properties of ibuprofen are due to its ability to both decrease prostaglandin synthesis by inhibiting the activities of cyclooxygenases (COXs) and IκB kinase-β (IKK-β). However, the exact mechanisms that accounts for the anti-inflammatory effects of pelubiprofen are not reported. In this study, we investigated the molecular mechanisms how pelubiprofen modulates the inflammatory mediators in LPS-induced macrophages and carrageenan-induced acute inflammatory rat model. Pelubiprofen potently diminished PGE(2) productions through inhibition of COX enzyme activity (IC(50) values for COX-1 and COX-2 are 10.66 ± 0.99 and 2.88 ± 1.01 µM, respectively), but also reduced the expressions of COX-2, inducible nitric oxide (iNOS), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 at transcriptional level in LPS-induced RAW 264.7 cells. In addition, pelubiprofen attenuated the LPS-induced transcription activity and the DNA binding activity of NF-κB, which was accompanied by a parallel reduction of degradation and phosphorylation of inhibitory kappa B-α (IκB-α) and consequently by decreased nuclear translocation of NF-κB. Furthermore, pelubipofen inhibited the LPS-induced phosphorylation of IKK-β and transforming growth factor-β activated kinase-1 (TAK1). In acute inflammatory rat model, pretreatment with pelubiprofen inhibited carrageenan-induce edema, neutrophil migration, PGE(2) production, and p65, a subunit of NF-κB, nuclear translocation in inflamed paw. Taken together, our data indicated that pelubiprofen is involved in the dual inhibition of COX activity and TAK1-IKK-NF-κB pathway, revealing molecular basis for the anti-inflammatory properties of pelubiprofen.
培鲁布洛芬是一种非甾体抗炎药(NSAIDs),在结构和药理学上与布洛芬有关。布洛芬的抗炎特性归因于其通过抑制环氧化酶(COXs)和 IκB 激酶-β(IKK-β)的活性来减少前列腺素合成的能力。然而,培鲁布洛芬抗炎作用的确切机制尚未报道。在这项研究中,我们研究了培鲁布洛芬调节脂多糖诱导的巨噬细胞和角叉菜胶诱导的急性炎症大鼠模型中炎症介质的分子机制。培鲁布洛芬通过抑制 COX 酶活性(COX-1 和 COX-2 的 IC50 值分别为 10.66±0.99 和 2.88±1.01µM)强烈减少 PGE2 的产生,但也降低了 COX-2、诱导型一氧化氮合酶(iNOS)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)和 IL-6 在 LPS 诱导的 RAW 264.7 细胞中的转录表达。此外,培鲁布洛芬减弱了 LPS 诱导的 NF-κB 的转录活性和 DNA 结合活性,这伴随着抑制性κB-α(IκB-α)的降解和磷酸化的平行减少,从而导致 NF-κB 的核易位减少。此外,培鲁布洛芬抑制了 LPS 诱导的 IKK-β 和转化生长因子-β激活激酶-1(TAK1)的磷酸化。在急性炎症大鼠模型中,培鲁布洛芬预处理抑制了角叉菜胶诱导的水肿、中性粒细胞迁移、PGE2 的产生以及 p65(NF-κB 的一个亚单位)在发炎的爪子中的核易位。总之,我们的数据表明培鲁布洛芬参与 COX 活性和 TAK1-IKK-NF-κB 途径的双重抑制,为培鲁布洛芬的抗炎特性提供了分子基础。